儿童门冬酰胺酶相关胰腺炎药学监护  

Pharmaceutical Care of Asparaginase-associated Pancreatitis in Children

作　　者：付强[1] 赵雪莲[2] 郭华[1] 邵云[1] 王培[1] 任艳丽[1] FU Qiang;ZHAO Xuelian;GUO Hua;SHAO Yun;WANG Pei;REN Yanli(Department of Pharmacy,The Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Pediatric Hematology,The Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第三附属医院药学部,郑州450052 [2]郑州大学第三附属医院小儿血液科,郑州450052

出　　处：《中国现代应用药学》2020年第6期728-731,共4页Chinese Journal of Modern Applied Pharmacy

基　　金：河南省科技发展计划项目(172102310318)。

摘　　要：目的探讨门冬酰胺酶使用过程中的药学监护要点。方法临床药师参与并发门冬酰胺酶相关胰腺炎儿童急性淋巴细胞白血病治疗,依据相关指南和最新循证医学证据,建立门冬酰胺酶相关胰腺炎药学监护要点。结果药学监护要点为门冬酰胺酶相关胰腺炎较早和快速识别;门冬酰胺酶相关胰腺炎治疗药物方案建立与调整;评估门冬酰胺酶相关胰腺炎患儿是否可再次使用门冬酰胺酶。结论通过药学监护,快速识别和管理门冬酰胺酶相关胰腺炎有助于确保患儿从门冬酰胺酶疗法中获得最大益处。OBJECTIVE To explore the key points of pharmaceutical care in the use of asparaginase. METHODS According to participation of clinical pharmacists in the treatment of acute lymphoblastic leukemia in children with asparaginase-associated pancreatitis, the key points of pharmaceutical care were established based on relevant guidelines and the latest evidence based medicine. RESULTS The key points of pharmaceutical care was: the earlier and rapid identification of asparaginase-associated pancreatitis;establishment and adjustment of therapeutic regimens for asparaginase-associated pancreatitis;assessment of the risk of re-exposing patients who suffered an episode of asparaginase-associated pancreatitis to asparaginase. CONCLUSION The pharmaceutical care to rapidly identify and manage asparaginase-associated pancreatitis will help ensure pediatric patients receive the maximal benefit from asparaginase therapy.

关 键 词：门冬酰胺酶 门冬酰胺酶相关胰腺炎 药学监护 儿童 急性淋巴细胞白血病 

分 类 号：R969.4[医药卫生—药理学]